<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215071</url>
  </required_header>
  <id_info>
    <org_study_id>AB 25/02</org_study_id>
    <nct_id>NCT01215071</nct_id>
  </id_info>
  <brief_title>Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA</brief_title>
  <official_title>Prospektiv Randomisierte Studie Zum Vergleich Einer Ausgedehnten Mit Einer eingeschränkten Pelvinen Lymphadenektomie Bei Der Operativen Therapie Des Harnblasenkarzinoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urogenital Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Urogenital Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is meant to evaluate the influence of different extension of pelvic lymphadenectomy on
      outcome of patients with bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The extention of pelvic lymphadenectomy in the surgical treatment of muscle-invasive,
      clinically locally bladder cancer is not yet standardized. There are no data from
      prospective studies on the prognostic significance of regional lymphadenectomy.

      Results of retrospective studies suggest, that the prognosis of patients with
      muscle-invasive bladder cancer can be improved by extending the limits of pelvic
      lymphadenectomy. Furthermore it could be demonstrated in a prospective study that the
      pattern of metastasis of bladder cancer has a high variability. About two-thirds of lymph
      node metastases are found outside the normally cleared areas of lymphadenectomy. In his
      study patients will be randomized into arms with limited versus extended lymphadenectomy.

      The limited lymphadenectomy includes the removal of the obturatorical and external iliac
      lymph nodes, the extended one includes the removal of all lymph nodes between pelvic floor
      and the departure of the inferior mesenteric artery. The primary objective of the study is
      to record the progression-free survival. Secondary study objectives include the creation of
      a standard for the surgical treatment and development of quality criteria and implementation
      of those into international guidelines. The indication for adjuvant chemotherapy for locally
      advanced tumors is not affected.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of type and location of tumour progression(local recurrences and distant metastases)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-specific survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of adjuvant chemotherapy (by subgroup analysis)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of complications</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on histopathological stage (Will Rogers phenomenon)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>limited lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fields 5, 7, 9, 11, 13, 14 are removed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>extended lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>limited lymphadenectomy</intervention_name>
    <description>Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)</description>
    <arm_group_label>limited lymphadenectomy</arm_group_label>
    <other_name>eingeschränkte Lymphadenektomie</other_name>
    <other_name>eingeschränkte LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>extended lymphadenectomy</intervention_name>
    <description>Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)</description>
    <arm_group_label>extended lymphadenectomy</arm_group_label>
    <other_name>ausgedehnte Lymphadenektomie</other_name>
    <other_name>ausgedehnte LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically, muscle-invasive bladder cancer, locally completely resectable(T2 -
             T4a, Nx)

          -  Age &gt;= 18 years

          -  Written consent of the patient

          -  Patient compliance and geographic proximity to allow adequate follow-up

        Exclusion Criteria:

          -  Histologically or by imaging diagnostics proven organ metastases

          -  Radiographic evidence of enlarged lymph nodes (&gt; 1 cm) above the aortic bifurcation
             in conjunction with pelvic lymph node metastases

          -  Radiographic or other evidence of T4b-tumor (infiltration of the pelvic wall or other
             organ systems)

          -  Prior neoadjuvant chemotherapy of bladder cancer

          -  Prior previous pelvic lymphadenectomy

          -  Prior radiotherapy to the pelvis

          -  internal medical or anesthetic risk factors that require a short operation time

          -  Palliative cystectomy (f.e. bulky-disease, infiltration of adjacent structures)

          -  Evidence of another tumor restricting life expectancy of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen E. Gschwend, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUO Arbeitsgemeinschaft Urologische Onkologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological hospital, Städt. Kliniken Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of urology, städt. Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological department of the hospital Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Hospital Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Holweide</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological hospital, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.auo-online.de</url>
    <description>The AUO Homepage where this study is presented</description>
  </link>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 7, 2011</lastchanged_date>
  <firstreceived_date>September 29, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphadenectomy</keyword>
  <keyword>Extension</keyword>
  <keyword>Bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
